Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy in the Treatment of Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

• Status: RECRUITING
• Trial end date: 2029-12-31

Summary

The goal of this Phase II clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) combined with SOX chemotherapy (S-1 plus Oxaliplatin) in patients with previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer.

The main questions it aims to answer are:

1What is the objective response rate (ORR) of the combination of QL1706 and SOX chemotherapy? 2What are the safety and tolerability of this combination therapy? Participants will

1. Receive Iparomlimab and Tuvonralimab (QL1706) via intravenous infusion every 3 weeks.

2. Receive SOX chemotherapy (Oxaliplatin via intravenous infusion on Day 1 and S-1 orally twice daily for 14 days) every 3 weeks for up to 6 cycles.

3. Continue maintenance therapy with QL1706 combined with S-1 after 6 cycles until disease progression or unacceptable toxicity.

4. Undergo tumor imaging assessments (CT or MRI) every 6 weeks for the first 24 weeks, and then every 9 weeks thereafter to monitor the disease.

• Phase: PHASE2

Details

• Lead Sponsor: Beijing Friendship Hospital